Volume 2 Supplement 1

35te Tagung der Pathologen am Oberrhein/35th Meeting of Pathologists of the Upper Rhine Region (PATOR)

Open Access

Diagnosis of Burkitt's lymphoma in due time: a practical approach

  • SB Cogliatti1,
  • U Novak2,
  • S Henz3,
  • U Schmid1,
  • P Möller4 and
  • TFE Barth4
Diagnostic Pathology20072(Suppl 1):S6

DOI: 10.1186/1746-1596-2-S1-S6

Published: 14 March 2007


The quick diagnosis of Burkitt's lymphoma (BL) and its clear-cut differentiation from diffuse large B-cell lymphoma (DLBCL) is of great clinical importance since treatment for these two disease entities differ markedly and should promptly be initiated in BL. However, these two tumours are difficult to distinguish using the current WHO classification, particularly in regard to BL variants, i.e., BL with plasmacytoid differentiation and atypical Burkitt's/Burkitt's-like lymphomas.


We studied 39 cases of highly proliferative blastic B-cell lymphoma (HPBCL) to establish a practical differential-diagnostic algorithm. Characteristics set for BL were a typical morphology, a mature B-cell phenotype of CD10+, Bcl-6+ and Bcl-2- tumour cells, a proliferation rate of >95%, and the presence of C-MYC rearrangements in the absence of t(14;18)(q32;q21). All cases were selectively negative for cyclin D-1, CD5, CD23, LMP-EBV, CD34 and TdT, and there were no cases of endemic or immunodeficiency-associated Burkitt's lymphoma.


Altogether the set BL characteristics were found in only 5/39 cases (12.8%), whereas the majority of tumours revealed mosaic features (87.2%). In a second attempt, we followed a pragmatic stepwise approach for a classification algorithm that includes the assessment of C-MYC status to stratify HPBCL into four predefined diagnostic categories (DC), namely DC I (5/39, 12.8%): "classical BL", corresponding to the classical variant of sporadic BL in the WHO classification; DC II (11/39, 28.2%): "atypical BL", corresponding to the atypical Burkitt's/Burkitt's-like variants of sporadic BL in the WHO classification; DC III (9/39, 23.1%): "C-MYC+ DLBCL"; and DC IV (14/39, 35.9%): "C-MYC- HPBCL".


This proposal may serve as a robust and objective operational basis for therapeutic decisions for HPBCL within one week and is applicable to be evaluated for its prognostic relevance in prospective clinical trials.

Authors’ Affiliations

Department of Pathology, Kantonsspital
Institute for Cancer Genetics, Columbia University
Department of Internal Medicine, Kantonsspital
Department of Pathology, University Hospital


© Cogliatti et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd.